Isatuximab Clinical Trials
21 recruitingDrug
Phase 218Phase 13Phase 33
Showing 1–20 of 21 trials
Recruiting
Phase 3
Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma
Multiple Myeloma
Canadian Cancer Trials Group570 enrolled28 locationsNCT06182774
Recruiting
Phase 1Phase 2
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Plasma Cell Myeloma Refractory
Sanofi258 enrolled28 locationsNCT04643002
Recruiting
Phase 2
Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
Multiple Myeloma
Canadian Myeloma Research Group75 enrolled7 locationsNCT05272826
Recruiting
Phase 2
Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation
Blood CancerRefractory Immune Cytopenias
Memorial Sloan Kettering Cancer Center12 enrolled7 locationsNCT05873205
Recruiting
Phase 2
Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
Multiple Myeloma
University of Illinois at Chicago50 enrolled2 locationsNCT05344833
Recruiting
Phase 3
Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
Multiple Myeloma
University of Heidelberg Medical Center411 enrolled69 locationsNCT06216158
Recruiting
Phase 2
Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency
Multiple Myeloma
Medical College of Wisconsin41 enrolled1 locationNCT04240054
Recruiting
Phase 1
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Multiple Myeloma
Regeneron Pharmaceuticals317 enrolled42 locationsNCT05137054
Recruiting
Phase 2
Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia
T-ALL
Goethe University40 enrolled14 locationsNCT06648889
Recruiting
Phase 2
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
Multiple MyelomaRelapsed CancerRefractory Multiple Myeloma
Massachusetts General Hospital50 enrolled2 locationsNCT05922501
Recruiting
Phase 2
Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma
Multiple MyelomaPlasma Cell Leukemia
University of Utah40 enrolled1 locationNCT06517017
Recruiting
Phase 2
Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
Multiple Myeloma
M.D. Anderson Cancer Center61 enrolled1 locationNCT05776979
Recruiting
Phase 2
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
CancerMultiple Myeloma
UNC Lineberger Comprehensive Cancer Center50 enrolled5 locationsNCT05145400
Recruiting
Phase 2
Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)
De Novo Multiple MyelomaAnitocabtagene Autoleucel
PETHEMA Foundation30 enrolled10 locationsNCT07045909
Recruiting
Phase 2
Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma
Smouldering Myeloma
University College, London63 enrolled2 locationsNCT06762769
Recruiting
Phase 2
Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance
Monoclonal Gammopathy
Columbia University27 enrolled2 locationsNCT04614558
Recruiting
Phase 2
Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
Non-Hodgkin LymphomaMultiple MyelomaLymphoma+1 more
Divaya Bhutani39 enrolled2 locationsNCT05346809
Recruiting
Phase 1Phase 2
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Multiple MyelomaNHLRefractory Non-Hodgkin Lymphoma+1 more
Indapta Therapeutics, INC.128 enrolled12 locationsNCT06119685
Recruiting
Phase 2Phase 3
Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients
Newly Diagnosed Multiple Myeloma
University Hopsital Schleswig Holstein Campus Lübeck100 enrolled6 locationsNCT05665140
Recruiting
Phase 2
Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma
Multiple Myeloma
Karolinska Institutet62 enrolled1 locationNCT04558931